NASDAQ:BFRA
Delisted
Biofrontera AG Stock News
$2.67
+0 (+0%)
At Close: Aug 17, 2022
Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021
08:55am, Thursday, 12'th Aug 2021
Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing i
Biofrontera Pursues Spin-Out IPO Plan
12:49am, Thursday, 12'th Aug 2021
Biofrontera Pursues Spin-Out IPO Plan
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
04:15am, Friday, 23'rd Jul 2021
Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für k
Biofrontera Inc.: U.S. Subsidiary Of German Dermatology Company Files S-1
02:21pm, Tuesday, 13'th Jul 2021
Biofrontera Inc. is presently a wholly owned U.S. subsidiary of Biofrontera AG (BFRA).
Biofrontera Inc. seeks IPO in the USA
05:59pm, Tuesday, 06'th Jul 2021
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc.
Biofrontera reports preliminary revenue for the month of June 2021
10:00am, Tuesday, 06'th Jul 2021
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported prel
Biofrontera reports preliminary revenue for the month of May 2021
10:01am, Monday, 07'th Jun 2021
Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported prel
Biofrontera reports Q1 2021 financial results
10:41am, Tuesday, 11'th May 2021
Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its f
Biofrontera reports preliminary revenue for the month of April 2021
07:23am, Thursday, 06'th May 2021
Leverkusen, Germany, May 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preli
Biofrontera AG: First quarter conference call to be held on May 12, 2021
09:40am, Monday, 03'rd May 2021
Leverkusen, Germany, May 03, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing it
Biofrontera AG (BFRA) CEO Hermann Lübbert on Q4 2020 Results - Earnings Call Transcript
02:26pm, Tuesday, 13'th Apr 2021
Biofrontera AG (BFRA) CEO Hermann Lübbert on Q4 2020 Results - Earnings Call Transcript
Biofrontera reports results for the 2020 financial year
01:57pm, Monday, 12'th Apr 2021
Leverkusen, Germany, April 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its
Biofrontera announces preliminary revenue for Q1 2021
10:30am, Thursday, 08'th Apr 2021
Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported pre
Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results
10:12am, Wednesday, 31'st Mar 2021
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing
Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp
03:40am, Wednesday, 31'st Mar 2021
Leverkusen, Germany, March 31, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced th
